Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MDL 800 is an allosteric activator of sirtuin 6 (SIRT6).1 It selectively activates SIRT6 deacetylase activity over SIRT1-5 and -7 and histone deacetylase 1 (HDAC1) and HDAC2-11 deacetylase activity in cell-free assays at 100 µM. It induces histone deacetylation (IC50 = 23.3 µM) in, and reduces proliferation of, BEL-7405 hepatocellular carcinoma (HCC) cells (EC50 = 90.4 µM). MDL 800 (0.1-5 µM) inhibits TNF-α release induced by oxygen and glucose deprivation (OGD) in primary mouse microglia.2 In vivo, MDL 800 (50, 100, and 150 mg/kg) reduces tumor weight and volume in a BEL-7405 HCC mouse xenograft model.1
WARNING This product is not for human or veterinary use.
1. Identification of a cellularly active SIRT6 allosteric activator. Nat. Chem. Biol. 14(12), 1118-1126 (2018).
2. A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis. Acta Pharm. Sin. B 11(3), 708-726 (2021).